Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)171.73
  • Today's Change3.97 / 2.37%
  • Shares traded6.81m
  • 1 Year change+23.79%
  • Beta0.5696
Data delayed at least 15 minutes, as of Nov 21 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments12,8169,2299,830
Total Receivables, Net11,15511,2549,977
Total Inventory4,0993,5793,128
Prepaid expenses4,9324,4014,993
Other current assets, total------
Total current assets33,00228,46327,928
Property, plant & equipment, net5,7335,6725,872
Goodwill, net32,29332,15632,379
Intangibles, net55,61067,43975,951
Long term investments304241277
Note receivable - long term------
Other long term assets7,7694,8344,122
Total assets134,711138,805146,529
LIABILITIES
Accounts payable3,6882,9342,882
Accrued expenses15,59512,25410,217
Notes payable/short-term debt01.0014
Current portion long-term debt/capital leases7,1914,13512,481
Other current liabilities, total4,7354,1492,543
Total current liabilities37,84129,53835,194
Total long term debt52,19459,13564,189
Total debt59,38563,27176,684
Deferred income tax1,9522,1903,009
Minority interest373328
Other liabilities, total32,32730,65528,701
Total liabilities124,351121,551131,121
SHAREHOLDERS EQUITY
Common stock181818
Additional paid-in capital20,18019,24518,305
Retained earnings (accumulated deficit)(1000)4,7843,127
Treasury stock - common(6533)(4594)(3143)
Unrealized gain (loss)------
Other equity, total(2305)(2199)(2899)
Total equity10,36017,25415,408
Total liabilities & shareholders' equity134,711138,805146,529
Total common shares outstanding1,7661,7691,768
Treasury shares - common primary issue574535
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.